Meeting
2014 Genitourinary Cancers Symposium
A pilot study of supraphysiologic testosterone (T) and oral etoposide (E) in men with castrate-resistant prostate cancer (CRPC).
Authors
Michael Thomas Schweizer
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Michael Thomas Schweizer , Emmanuel S. Antonarakis , Hao Wang , Avery N. Spitz , Haiyi Cao , Alberto Pacheco , Mario A. Eisenberger , Michael Anthony Carducci , Samuel R. Denmeade
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01084759
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 45)
DOI
10.1200/jco.2014.32.4_suppl.45
Abstract #
45
Poster Bd #
D1
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).
First Author: Julia Chen
Poster
2018 Genitourinary Cancers Symposium
A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
First Author: Chong-xian Pan
Poster
2018 Genitourinary Cancers Symposium
An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi Neklesa
Poster
2017 ASCO Annual Meeting
Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.
First Author: Susan F. Slovin